<DOC>
	<DOCNO>NCT01844635</DOCNO>
	<brief_summary>The objective study evaluate feasibility effectiveness immunosuppressive therapy ( IST ) use rabbit anti-thymocyte globulin ( ATG ) ( Thymoglobuline , Genzyme ) patient severe aplastic anemia ( VSAA ) severe aplastic anemia ( SAA ) primary therapy . The primary endpoint response rate ( complete response ( CR ) + partial response ( PR ) ) day 180 start IST . Secondary endpoint include evaluation presence frequency Epstein-Barr virus ( EBV ) -reactivation EBV-associated lymphoproliferative disorder ( EBV-LPD ) , Cytomegalovirus ( CMV ) -reactivation CMV associate disease , response rate ( CR+PR ) Day 360 start IST , relapse rate overall survival .</brief_summary>
	<brief_title>Randomised Study Comparing Different Dosages Rabbit ATG Patients With SAA</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Acquired aplastic anemia Age : young 70 year old Severity : SAA , VSAA . Interval diagnosis registration &lt; 6 month . Written inform consent caretaker and/or whenever possible consent patient .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>